{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114224","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.931469+00:00","generated_at":"2026-06-22T09:32:59.068865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Replimune Q2 net loss $43.1M; CERPASS enrollment complete, cash runway extended into 2025","bullets":["Net loss of $43.1M for Q2 FY2022 (vs $29.4M in Q2 FY2021); R&D expenses $28.8M.","Completed enrollment in CERPASS trial (n=211) of RP1+Libtayo in CSCC; primary data expected H1 2023.","Six-month data from first 75 patients in IGNYTE (RP1+Opdivo anti-PD1 failed melanoma) expected by year-end.","Closed $200M term loan with Hercules Capital; cash and investments $371.8M as of Sep 30, 2022.","Cash runway extended into 2025, covering commercial infrastructure and confirmatory trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114224","json":"https://secwatch.observer/filing/0001104659-22-114224.json","markdown":"https://secwatch.observer/filing/0001104659-22-114224.md","text":"https://secwatch.observer/filing/0001104659-22-114224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465922114224/0001104659-22-114224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465922114224/tm2229523d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:32:59.068865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e53635adbf214a542928b5229c5d3a3f3893fd3","claim":"Replimune Group, Inc. reported financial results for second quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Replimune Group, Inc. issued a news release announcing its financial results for the second quarter ended September 30, 2022 and certain corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465922114224/0001104659-22-114224-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}